Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

GLYBURIDE 1.25 MG TABLET

Glyburide
$0.0666per EA

Strength

1.25 mg/1

Manufacturer

Teva Pharmaceuticals USA Inc.

NDC

00093834201

Classification

Generic

Dosage Form

TABLET

Route

ORAL

Last Updated

4/22/2026

Active Ingredients

GLYBURIDE

Approval Type

Generic (ANDA)

FDA Application

ANDA074388

On Market Since

8/30/1995

Pharmacological Classes

Sulfonylurea Compounds
Sulfonylurea

Price History

1W

0.0%

1M

-3.4%

3M

-9.9%

6M

-23.7%

1Y

-7.8%

3Y

-8.2%

5Y

-50.9%

All

-44.7%

Generic Alternatives

1 alternative • Same active ingredient

GLYBURIDE 1.25 MG TABLET
Generic
72241003805•Modavar Pharmaceuticals LLC
$0.0666

Related Drugs

Same classification

GLIMEPIRIDE 1 MG TABLET
Generic
16571077301•Rising Pharma Holdings Inc.
$0.0225
per EA
GLIMEPIRIDE 1 MG TABLET
Generic
16571077350•Rising Pharma Holdings Inc.
$0.0225
per EA
GLIMEPIRIDE 1 MG TABLET
Generic
16729000116•Accord Healthcare Inc.
$0.0225
per EA
GLIMEPIRIDE 1 MG TABLET
Generic
42571010001•Micro Labs Limited
$0.0225
per EA
GLIMEPIRIDE 1 MG TABLET
Generic
43547039410•Solco Healthcare US LLC
$0.0225
per EA
GLIMEPIRIDE 1 MG TABLET
Generic
43547039450•Solco Healthcare US LLC
$0.0225
per EA
GLIMEPIRIDE 1 MG TABLET
Generic
50268035815•AvPAK
$0.0225
per EA
GLIMEPIRIDE 1 MG TABLET
Generic
55111032001•Dr. Reddy's Laboratories Inc.
$0.0225
per EA
GLIMEPIRIDE 1 MG TABLET
Generic
55111032005•Dr. Reddy's Laboratories Inc.
$0.0225
per EA
GLIMEPIRIDE 1 MG TABLET
Generic
61442011501•Carlsbad Technology Inc.
$0.0225
per EA

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy